Log in

NASDAQ:PDEXPro-Dex Stock Price, Forecast & News

$20.75
+0.51 (+2.52 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.75
Now: $20.75
$20.75
50-Day Range
$17.00
MA: $18.75
$20.80
52-Week Range
$11.40
Now: $20.75
$23.90
Volume700 shs
Average Volume8,736 shs
Market Capitalization$80.30 million
P/E Ratio19.04
Dividend YieldN/A
Beta1.18
Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.79 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PDEX
CUSIPN/A
Phone949-769-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.17 million
Cash Flow$1.12 per share
Book Value$4.14 per share

Profitability

Net Income$4.15 million

Miscellaneous

Employees80
Market Cap$80.30 million
Next Earnings Date9/3/2020 (Estimated)
OptionableNot Optionable
$20.75
+0.51 (+2.52 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PDEX News and Ratings via Email

Sign-up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions

How has Pro-Dex's stock been impacted by COVID-19 (Coronavirus)?

Pro-Dex's stock was trading at $18.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PDEX stock has increased by 13.8% and is now trading at $20.75.
View which stocks have been most impacted by Coronavirus
.

When is Pro-Dex's next earnings date?

Pro-Dex is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020.
View our earnings forecast for Pro-Dex
.

How were Pro-Dex's earnings last quarter?

Pro-Dex Inc (NASDAQ:PDEX) released its earnings results on Thursday, May, 7th. The medical instruments supplier reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.08. The medical instruments supplier had revenue of $8.51 million for the quarter. Pro-Dex had a net margin of 14.50% and a return on equity of 25.64%.
View Pro-Dex's earnings history
.

Has Pro-Dex been receiving favorable news coverage?

Media stories about PDEX stock have trended extremely negative on Sunday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pro-Dex earned a daily sentiment score of -4.8 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Pro-Dex
.

Who are some of Pro-Dex's key competitors?

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), AT&T (T), Bank of America (BAC), Enterprise Products Partners (EPD), Micron Technology (MU), NovaBay Pharmaceuticals (NBY), NVIDIA (NVDA), AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR) and Alibaba Group (BABA).

Who are Pro-Dex's key executives?

Pro-Dex's management team includes the following people:
  • Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
  • Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)

What is Pro-Dex's stock symbol?

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

Who are Pro-Dex's major shareholders?

Pro-Dex's stock is owned by many different institutional and retail investors. Top institutional shareholders include LSV Asset Management (1.35%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson and Raymond E Cabillot.
View institutional ownership trends for Pro-Dex
.

Which major investors are buying Pro-Dex stock?

PDEX stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management.
View insider buying and selling activity for Pro-Dex
.

How do I buy shares of Pro-Dex?

Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pro-Dex's stock price today?

One share of PDEX stock can currently be purchased for approximately $20.75.

How big of a company is Pro-Dex?

Pro-Dex has a market capitalization of $80.30 million and generates $27.17 million in revenue each year. Pro-Dex employs 80 workers across the globe.

What is Pro-Dex's official website?

The official website for Pro-Dex is www.pro-dex.com.

How can I contact Pro-Dex?

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.